Skip to main content
. 2022 Mar 15;23(6):3175. doi: 10.3390/ijms23063175

Figure 1.

Figure 1

Functional evaluation of the elexacaftor-based combinations on nasal epithelia derived from CF patients bearing the F508del mutation. (A) Representative traces of the effect of the vehicle alone (DMSO) or Elexa (3 µM), or Elexa/Teza (3 µM/10 µM) or ETI (3 µM/10 µM/5 µM) in F508del/G542X nasal epithelial cells (derived from donor ID: TT001) with the short-circuit current technique. (B) Scatter dot plot showing the summary of results obtained from experiments described in (A) Data reported are the amplitude of the current blocked by 20 µM inh-172 (ΔIscinh-172). (C) Representative traces of the effect of treatment with modulators (same conditions tested in (A)) on F508del/F508del nasal epithelial cells (derived from donor ID: TT003) using the short-circuit current technique. (D) Scatter dot plot showing the summary of ΔIscinh-172 data obtained from experiments described in (C). Asterisks indicate statistical significance of the treatments vs. control (DMSO-treated): ** p < 0.01; *** p < 0.001.